Overview

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Status:
Completed

Trial end date:
2017-04-18

Target enrollment:

Participant gender:

Summary

A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Medivation, Inc.